{"id":"cabergoline-tablets","safety":{"commonSideEffects":[{"rate":"10-30%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-15%","effect":"Dizziness"},{"rate":"5-10%","effect":"Fatigue"},{"rate":"5-10%","effect":"Abdominal pain"},{"rate":"5-10%","effect":"Orthostatic hypotension"}]},"_chembl":{"chemblId":"CHEMBL1201087","moleculeType":"Small molecule","molecularWeight":"451.62"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cabergoline binds to dopamine D2 receptors on lactotroph cells in the pituitary, mimicking dopamine's natural inhibitory effect on prolactin release. This leads to sustained suppression of elevated prolactin levels. It is used to treat hyperprolactinemia and prolactin-secreting pituitary adenomas (prolactinomas).","oneSentence":"Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:04:34.610Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hyperprolactinemia"},{"name":"Prolactin-secreting pituitary adenoma (prolactinoma)"}]},"trialDetails":[{"nctId":"NCT07492160","phase":"PHASE2","title":"Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","status":"RECRUITING","sponsor":"Maimonides Medical Center","startDate":"2026-03-16","conditions":"Pregnancy, Abortion","enrollment":348},{"nctId":"NCT07386080","phase":"PHASE4","title":"Carbergoline for Antipsychotic Induced Hyperprolactinemia.","status":"NOT_YET_RECRUITING","sponsor":"Zealand University Hospital","startDate":"2026-05-01","conditions":"Scizophrenia","enrollment":146},{"nctId":"NCT07255911","phase":"NA","title":"Cabergoline & Letrozole Versus Letrozole in Ovulation Induction in PCOS","status":"RECRUITING","sponsor":"Mst.Sumyara Khatun","startDate":"2025-02-07","conditions":"PCOS","enrollment":72},{"nctId":"NCT07072910","phase":"PHASE2","title":"Cabergoline for Episodic Migraine","status":"RECRUITING","sponsor":"Aarhus University Hospital","startDate":"2025-11-12","conditions":"Migraine","enrollment":150},{"nctId":"NCT07008417","phase":"PHASE1","title":"A Study on Bioequivalence of Cabergoline Tablets in Human Body","status":"ACTIVE_NOT_RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-06-30","conditions":"Hyperprolactinemia","enrollment":72},{"nctId":"NCT07124221","phase":"PHASE3","title":"A Phase III Clinical Study of Cabergoline Tablets Compared With Bromocriptine Mesylate Tablets","status":"RECRUITING","sponsor":"Changchun GeneScience Pharmaceutical Co., Ltd.","startDate":"2025-09-12","conditions":"Hyperprolactinemia","enrollment":382},{"nctId":"NCT07045935","phase":"PHASE4","title":"Metabolic Outcomes in Patients With Prolactinomas Under Dopamine Agonist Treatment","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2025-09-16","conditions":"Prolactinoma","enrollment":60},{"nctId":"NCT07168837","phase":"NA","title":"Letrozole and Cabergoline Versus Letrozole Alone in Ovulation Induction","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2023-01-10","conditions":"PCOS (Polycystic Ovary Syndrome)","enrollment":100},{"nctId":"NCT07034859","phase":"PHASE4","title":"Cabergoline in the Management of Nonfunctioning Pituitary Adenoma","status":"ENROLLING_BY_INVITATION","sponsor":"National Taiwan University Hospital","startDate":"2024-05-20","conditions":"Pituitary Adenoma, MRI, RCT","enrollment":30},{"nctId":"NCT06333691","phase":"NA","title":"Comparative Study Between Calcium Gluconate With Diosmin, Cabergoline and Cabergoline With Diosmin","status":"COMPLETED","sponsor":"Minia University","startDate":"2022-10-01","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":180},{"nctId":"NCT01794793","phase":"PHASE4","title":"Study to Allow Access to Pasireotide for Patients Benefiting From Pasireotide Treatment in Novartis-sponsored Studies","status":"COMPLETED","sponsor":"RECORDATI GROUP","startDate":"2013-06-10","conditions":"Cushing's Disease, Acromegaly, Neuroendocrine Tumors","enrollment":337},{"nctId":"NCT06123026","phase":"PHASE4","title":"Pharmacological Inhibition of Lactation After 16 to 20 Week Abortion","status":"RECRUITING","sponsor":"Northwestern University","startDate":"2023-12-18","conditions":"Lactation Suppressed, Second Trimester Abortion","enrollment":200},{"nctId":"NCT05981742","phase":"PHASE2","title":"Effects of Combined Metformin and Cabergoline in Comparison With Metformin Only Therapy on Ovarian and Hormonal Activities in Iraqi Patients With PCOS","status":"COMPLETED","sponsor":"Al-Rasheed University College","startDate":"2022-09-21","conditions":"Polycystic Ovary Syndrome","enrollment":75},{"nctId":"NCT03457389","phase":"NA","title":"Comparison of Treatment Outcome of Cabergoline According to Target Prolactin Levels in Patients With Prolactinoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2018-02-22","conditions":"Pituitary Adenoma, Prolactinoma, Pituitary Tumor","enrollment":68},{"nctId":"NCT03714763","phase":"NA","title":"Dopamine D2 Receptors(D2R) Imaging in Nonfunctioning Pituitary Adenoma(NFPA)","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-11-01","conditions":"Pituitary Adenoma","enrollment":50},{"nctId":"NCT03400865","phase":"NA","title":"Cabergoline Combined Hydroxychloroquine/Chloroquine to Treat Resistant Prolactinomas","status":"UNKNOWN","sponsor":"Zhebao Wu","startDate":"2018-10-25","conditions":"Resistance, Disease, Prolactinoma","enrollment":30},{"nctId":"NCT01535859","phase":"PHASE3","title":"Study of Cabergoline for Prevention of Ovarian Hyperstimulation Syndrome (OHSS) in In Vito Fertilization Cycles and Derivation of OHSS Biomarkers","status":"COMPLETED","sponsor":"KK Women's and Children's Hospital","startDate":"2012-04","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":46},{"nctId":"NCT03549741","phase":"PHASE2, PHASE3","title":"Cabergoline As An Adjuvant To Clomiphene Citrate For Management Of Unexplained Infertility","status":"UNKNOWN","sponsor":"Assiut University","startDate":"2018-07","conditions":"Infertility","enrollment":120},{"nctId":"NCT03473613","phase":"PHASE3","title":"Cabergoline Versus Calcium Infusion in Ovarian Hyperstimulation Syndrome Prevention","status":"COMPLETED","sponsor":"Benha University","startDate":"2014-10-01","conditions":"Ovarian Hyperstimulation","enrollment":230},{"nctId":"NCT00652873","phase":"PHASE1","title":"Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fed Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2001-07","conditions":"To Determine Bioequivalence Under Fed Conditions","enrollment":24},{"nctId":"NCT00033111","phase":"PHASE2","title":"A Study of Cabergoline for the Treatment of Cocaine Dependence - 1","status":"COMPLETED","sponsor":"National Institute on Drug Abuse (NIDA)","startDate":"2001-06","conditions":"Cocaine-Related Disorders, Substance-Related Disorders","enrollment":140},{"nctId":"NCT02644304","phase":"PHASE2","title":"Clomiphene Citrate Plus Cabergoline in Treatment of Polycystic Ovary Syndrome","status":"UNKNOWN","sponsor":"Woman's Health University Hospital, Egypt","startDate":"2015-05","conditions":"Female Reproductive Problem","enrollment":88},{"nctId":"NCT01009567","phase":"PHASE1, PHASE2","title":"Compare the Efficacy of Human Albumin With Cabergoline to Prevent Ovarian Hyper Stimulation in Assisted Reproductive Technology (ART) Program","status":"COMPLETED","sponsor":"Royan Institute","startDate":"2009-06","conditions":"Ovarian Hyperstimulation Syndrome","enrollment":10},{"nctId":"NCT01569256","phase":"NA","title":"Ovarian Hyperstimulation Syndrome and Cabergoline","status":"COMPLETED","sponsor":"Etlik Zubeyde Hanim Womens' Health and Teaching Hospital","startDate":"2008-03","conditions":"Polycystic Ovarian Syndrome, Ovarian Hyperstimulation Syndrome","enrollment":40},{"nctId":"NCT00627003","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2002-11","conditions":"Restless Legs Syndrome","enrollment":43},{"nctId":"NCT00625547","phase":"PHASE3","title":"A Study to Determine the Efficacy and Safety of Cabergoline for the Treatment of Patients With RLS","status":"COMPLETED","sponsor":"Pfizer","startDate":"2003-01","conditions":"Restless Legs Syndrome","enrollment":361},{"nctId":"NCT00653055","phase":"PHASE1","title":"Bioequivalence Study of Cabergoline Tablets and Dostinex Under Fasting Conditions","status":"COMPLETED","sponsor":"Par Pharmaceutical, Inc.","startDate":"2001-08","conditions":"To Determine Bioequivalence Under Fasting Conditions","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cabergoline tablets","genericName":"Cabergoline tablets","companyName":"Changchun GeneScience Pharmaceutical Co., Ltd.","companyId":"changchun-genescience-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cabergoline is a dopamine D2 receptor agonist that inhibits prolactin secretion from the anterior pituitary gland. Used for Hyperprolactinemia, Prolactin-secreting pituitary adenoma (prolactinoma).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}